Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Thursday. The brokerage issued a sell rating on the stock.

Other equities analysts also recently issued research reports about the company. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, February 18th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Price Performance

NYSE CANF opened at $1.76 on Thursday. Can-Fite BioPharma has a 1 year low of $1.29 and a 1 year high of $4.69. The stock has a market capitalization of $6.23 million, a PE ratio of -0.98 and a beta of 1.33. The business’s 50-day moving average is $1.58 and its 200 day moving average is $1.95.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned approximately 0.71% of Can-Fite BioPharma at the end of the most recent quarter. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.